Romosozumab ‘safe and effective’ in women with osteoporosis and CKD
A post-hoc analysis shows the biologic reduced fracture risk with similar adverse event rates across a range of renal function levels
Postmenopausal women with comorbid osteoporosis and mild-to-moderate chronic kidney disease can safely be prescribed romosozumab, US-led researchers say.
Their findings suggest that the monoclonal antibody remains highly effective across varying levels of renal function down to an eGFR of 30mL/min/1.73m2.
The findings are “reassuring”, the authors said, given the two-to-threefold greater risk of fracture and death in patients with both conditions compared to the general population.
Writing in the Journal of Bone and Mineral Research, the team reported results from a post-hoc analysis of two pivotal phase III trials to assess the efficacy and safety of romosozumab versus control across different eGFR levels.
